## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.55 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($260.76)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 10)

**1. Investors in The Cigna Group (CI) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today**
- Source: mypanhandle.com | 20251212T040754 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) concerning potential federal securities law violations. This comes after Cigna's stock price dropped significantly following its Q3 2025 earnings report, which revealed a higher Healthcare Medical Care Ratio (MCR) and reduced future profitability. The firm encourages affected investors to contact them for more information.

**2. Investors in The Cigna Group (CI) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today**
- Source: SiouxlandProud | 20251211T180816 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE: CI) for possible federal securities law violations. The probe follows Cigna's Q3 2025 earnings report, which revealed an increased Healthcare MCR of 84.8% and reduced future profitability, causing a 17% drop in stock price on October 30, 2025. The firm encourages affected investors to contact them for more information.

**3. Investigation Alert: The Cigna Group (CI) Under Scrutiny - Contact Levi & Korsinsky For Details**
- Source: WFXR News | 20251211T180813 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) concerning potential violations of federal securities laws. This follows CI's third-quarter 2025 earnings report on October 30, 2025, which revealed a Healthcare MCR of 84.8% (up from 82.8% in Q3 2024), leading to a significant 17% stock price drop. The firm is inviting investors to contact them for more information regarding this investigation.

**4. CI STOCK ALERT: Levi & Korsinsky Notifies The Cigna Group Investors of an Ongoing Investigation**
- Source: ACCESS Newswire | 20251215T140756 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) for potential federal securities law violations. This investigation follows CI's third-quarter 2025 earnings report, which revealed an increase in their Healthcare MCR to 84.8% from 82.8% in 2024, attributed to their Individual and Family Plans business and higher stop loss medical costs. This news led to a 17% drop in CI's stock price on October 30, 2025.

**5. Investigation Alert: The Cigna Group (CI) Under Scrutiny - Contact Levi & Korsinsky For Details**
- Source: WJTV | 20251212T100729 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (CI) for possible federal securities law violations. This follows a significant 17% stock price drop on October 30, 2025, after Cigna reported its third-quarter 2025 earnings, revealing a higher Healthcare MCR of 84.8% compared to 82.8% in the previous year, which is expected to reduce future profitability. The firm is inviting investors to contact them for more details regarding the potential lawsuit.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-12 | Bernstein | $294 | $346 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-12 | Bernstein | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 9.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 9.0x stretched relative to 4% growth. Balance sheet: $3.1B free cash flow. Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.4B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 9.0 |
| Current P/E | 9.3 |
| YoY Growth | 3.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.7% to 0.9% (+5.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 at 4.2% confirms short-term momentum alignment. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (0.63), confirming momentum. RSI neutral at 52. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.91% (CS: 46) | Neutral |
| RSI_14 | 52.2 | Neutral |
| MACD Histogram | 0.63 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 0.977x | Below |
| vs SMA200 | 0.907x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $274.70
- **Stop Loss:** $260.76 (5.1% risk)
- **Target:** $302.58 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $19,503.70
- **Portfolio %:** 19.50%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*